PODD
Insulet Corporation
NASDAQ: PODD · HEALTHCARE · MEDICAL DEVICES
$154.17
+4.65% today
Updated 2026-06-05
Market cap
$10.37B
P/E ratio
34.98
P/S ratio
3.58x
EPS (TTM)
$4.28
Dividend yield
—
52W range
$141 – $355
Volume
1.4M
WallStSmart proprietary scores
73
out of 100
Grade: B
Buy
Investment rating
10.0
Growth
A+7.0
Quality
B+7.5
Profitability
B+5.0
Valuation
C+5/9
Piotroski F-Score
Moderate
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$242.43
+57.25%
12-Month target
$104.44
-32.26%
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy17 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 23.25% — strong efficiency
+ Free cash flow $86.00M — positive
+ Revenue growth 33.90% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.31B | $1.70B | $2.07B | $2.71B | $2.90B |
| Net income | $4.60M | $206.30M | $418.30M | $247.10M | $91.10M |
| EPS | — | — | — | — | $4.28 |
| Free cash flow | $-38.30M | $70.10M | $305.40M | $377.70M | $86.00M |
| Profit margin | 0.35% | 12.16% | 20.19% | 9.12% | 10.40% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-03 | WEATHERMAN, ELIZABETH H | Buy | 3,450 | $144.20 |
| 2026-06-03 | STONESIFER, TIMOTHY C. | Buy | 2,790 | $143.51 |
| 2026-06-03 | BORIO, LUCIANA | Sale | 418 | $143.27 |
Peer comparison
Smart narrative
Insulet Corporation trades at $154.17. representing a P/E of 34.98x trailing earnings. Our Smart Value Score of 73/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.46, it sits in the grey zone. TTM revenue stands at $2.90B. with profit margins at 10.40%.
Frequently asked questions
What is Insulet Corporation's stock price?
Insulet Corporation (PODD) trades at $154.17, on a P/E of 35.0x and a P/S of 3.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Insulet Corporation overvalued?
Insulet Corporation carries a Smart Value Score of 73/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Insulet Corporation (PODD)?
The 12-month analyst consensus target is $242.43, about 57.2% above the current $154.17. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Insulet Corporation's revenue?
Insulet Corporation's trailing twelve-month revenue is $2.90B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Insulet Corporation's Altman Z-Score is 2.46, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.58x
ROE23.25%
Beta1.13
50D MA$169.67
200D MA$260.28
Shares out0.07B
Float0.07B
Short ratio—
Avg volume1.4M
Performance
1 week-12.12%
1 month-25.28%
3 months-37.78%
YTD-46.78%
1 year—
3 years—
5 years—